High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: A randomised controlled trial

European Journal of Endocrinology

Volumn 161, Issue 2, 2009, Pages 331-338

  Giustina, Andrea ^a   Bonadonna, Stefania ^a   Bugari, Giovanna ^a   Colao, Annamaria ^b   Cozzi, Renato ^c   Cannavo, Salvatore ^d   De Marinis, Laura ^e   Degli Uberti, Ettore ^f   Bogazzi, Fausto ^g   Mazziotti, Gherardo ^a   Minuto, Francesco ^h   Montini, Marcella ⁱ   Ghigo, Ezio ^j  

^a UNIVERSITY OF BRESCIA   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c OSPEDALE NIGUARDA CA GRANDA   (Italy)

^d UNIVERSITY OF MESSINA   (Italy)

^e CATHOLIC UNIVERSITY   (Italy)

^f UNIVERSITY OF FERRARA   (Italy)

^g UNIVERSITY OF PISA   (Italy)

^h UNIVERSITY OF GENOA   (Italy)

ⁱ Bergamo Hospital   (Italy)

^j UNIVERSITY OF TURIN   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; GROWTH HORMONE; OCTREOTIDE; SOMATOMEDIN C; SOMATOSTATIN; DRUG DERIVATIVE; HUMAN GROWTH HORMONE;

ABDOMINAL PAIN; ACROMEGALY; ADULT; AGED; ARTICLE; CHOLELITHIASIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FLATULENCE; GASTROINTESTINAL TOXICITY; GROWTH HORMONE BLOOD LEVEL; HORMONAL THERAPY; HUMAN; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; BLOOD; INTRAMUSCULAR DRUG ADMINISTRATION; METABOLISM; MIDDLE AGED;

ACROMEGALY; ADULT; AGED; FEMALE; HUMAN GROWTH HORMONE; HUMANS; INJECTIONS, INTRAMUSCULAR; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; OCTREOTIDE; PROSPECTIVE STUDIES; SOMATOSTATIN;

EID: 68349141978     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-09-0372     Document Type: Article

References (28)

1. Melmed S, Casanueva FF, Cavagnini F, Chanson P, Frohman L, Grossman A, Ho K, Kleinberg D, Lamberts S, Laws E, Lombardi G, Vance ML, Von Werder K, Wass J & Giustina A. Guidelines for acromegaly management. Journal of Clinical Endocrinology and Metabolism 2002 87 4054-4058.
2. Melmed S, Colao A, Barkan A, Molitch M, Grossman AB, Kleinberg D, Clemmons D, Chanson P, Laws E, Schlechte J, Vance ML, Ho K & Giustina A. Guidelines for acromegaly management: an update. Journal of Clinical Endocrinology and Metabolism 2009 94 1509-1517.
3. Gola M, Bonadonna S, Mazziotti G, Amato G & Giustina A. Resistance to somatostatin analogues in acromegaly: an evolving concept? Journal of Endocrinological Investigation 2006 29 86-93.
4. Colao A, Pivonello R, Auriemma RS, Galdiero M, Savastano S & Lombardi G. Beneficial effect of dose escalation of octreotide LAR as first-line therapy in patients with acromegaly. European Journal of Endocrinology 2007 157 579-587. (Pubitemid 350187374)
5. Bonadonna S, Manelli F, Burattin A, Villa S, Agabiti Rosei F & Giustina A. Shortening the intervals between octreotide LAR 30 mg intramuscular injections from 28 to 21 days may improve GH control in patients with active acromegaly (abstract). Journal of Endocrinological Investigation 2003 26 P271.
6. Woltering EA, Salvo VA, O'Dorisio TM, Lyons J, Li G, Zhou Y, Seward JR, Go VL, Vinik AI, Mamikunian P & Mamikunian G. Clinical value of monitoring plasma octreotide levels during chronic octreotide long-acting repeatable therapy in carcinoid patients. Pancreas 2008 37 94-100.
7. Giustina A, Barkan A, Casanueva FF, Cavagnini F, Frohman L, Ho K, Veldhuis J, Wass J, Von Werder K & Melmed S. Criteria for cure of acromegaly: a consensus statement. Journal of Clinical Endocrinology and Metabolism 2000 85 526-529. (Pubitemid 32273628)
8. Melmed S. Medical progress: acromegaly. New England Journal of Medicine 2006 355 2558-2573.
9. Melmed S, Casanueva F, Cavagnini F, Chanson P, Frohman LA, Gaillard R, Ghigo E, Ho K, Jaquet P, Kleinberg D, Lamberts S, Laws E, Lombardi G, Sheppard MC, Thorner M, Vance ML, Wass JAH & Giustina A. Consensus statement: medical management of acromegaly. European Journal of Endocrinology 2005 153 737-740. (Pubitemid 43020222)
10. Astruc B, Marbach P, Bouterfa H, Denot C, Safari M, Vitaliti A & Sheppard M. Long-acting octreotide and prolonged-release lanreotide formulations have different pharmacokinetic profiles. Journal of Clinical Pharmacology 2005 45 836-844. (Pubitemid 40875336)
11. Di Chiro G & Nelson KB. The volume of the sella turcica. American Journal of Radiology 1962 87 989-1008.
12. Grass P, Marbach P, Bruns C & Lancranjan J. Sandostatin LAR (microencapsulated octreotide acetate) in acromegaly: pharmacokinetic and pharmacodynamic relationships. Metabolism 1996 45 27-30.
13. Lamberts SW, van der Lely AJ, de Herder WW & Hofland LJ. Octreotide. New England Journal of Medicine 1996 334 246-254.
14. Tulipano G, Bonfanti C, Milani G, Billeci B, Bollati A, Cozzi R, Maira G, Murphy WA, Poiesi C, Turazzi S & Giustina A. Differential inhibition of growth hormone secretion by analogues selective for somatostatin receptor subtypes 2 and 5 in human growth-hormone-secreting adenoma cells in vitro. Neuroendocrinology 2001 73 344-351. (Pubitemid 32588858)
15. van der Hoek J, de Herder WW, Feelders RA, van der Lely AJ, Uitterlinden P, Boerlin V, Bruns C, Poon KW, Lewis I, Weckbecker G, Krahnke T, Hofland LJ & Lamberts SW. A single-dose comparison of the acute effects between the new somatostatin analog SOM230 and octreotide in acromegalic patients. Journal of Clinical Endocrinology and Metabolism 2004 89 638-645. (Pubitemid 38269871)
16. Hofland LJ & Lamberts SW. The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocrine Reviews 2003 24 28-47.
17. van der Lely AJ, Hutson RK, Trainer PJ, Besser GM, Barkan AL, Katznelson L, Klibanski A, Herman-Bonert V, Melmed S, Lee Vance M, Freda PU, Stewart PM, Friend KE, Clemmons DR, Johannsson G, Stavrou S, Cook DM, Phillips LS, Strasburger CJ, Hacker S, Zib KA, Davis RJ, Scarlett JA & Thorner MO. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 2001 358 1754-1759. (Pubitemid 33152999)
18. Feenstra J, de Herder WW, ten Have SM, van den Beld AW, Feelders RA, Janssen JA & van der Lely AJ. Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. Lancet 2005 365 1644-1646.
19. Castinetti F, Taieb D, Kuhn J-M, Chanson P, Tamura M, Jaquet P, Conte-Devolx B, Régis J, Dufour H & Brue T. Outcome of gamma knife radiosurgery in 82 patients with acromegaly: correlation with initial hypersecretion. Journal of Clinical Endocrinology and Metabolism 2005 90 4483-4488. (Pubitemid 41159330)
20. Ezzat S, Ren SG, Braunstein GD & Melmed S. Octreotide stimulates insulin-like growth factor-binding protein-1: a potential pituitary - independent mechanism for drug action. Journal of Clinical Endocrinology and Metabolism 1992 75 1459-1463. (Pubitemid 23001402)
21. Pokrajac A, Frystyk J, Flyvbjerg A & Trainer PJ. Pituitaryin- dependent effect of octreotide on IGF1 generation. European Journal of Endocrinology 2009 160 543-548.
22. Freda PU, Katznelson L, van der Lely AJ, Reyes CM, Zhou S & Rabinowitz D. Long-acting somatostatin analogue therapy of acromegaly: a meta-analysis. Journal of Clinical Endocrinology and Metabolism 2005 90 4465-4473. (Pubitemid 41159328)
23. Ayuk J, Clayton RN, Holder S, Sheppard MC, Stewart PM & Bates AS. Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-1 concentrations, predict excess mortality in patients with acromegaly. Journal of Clinical Endocrinology and Metabolism 2004 89 1613-1617. (Pubitemid 38507910)
24. Giustina A & Veldhuis JD. Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and human. Endocrine Reviews 1998 19 717-797. (Pubitemid 128506521)
25. Amato G, Mazziotti G, Rotondi M, Iorio S, Doga M, Sorvillo F, Manganella G, Di Salle F, Giustina A & Carella C. Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly. Clinical Endocrinology 2002 56 65-71. (Pubitemid 34107323)
26. Mazziotti G, Floriani I, Bonadonna S, Torri V, Chanson P & Giustina A. Effects of somatostatin analogues on glucose homeostasis: a meta-analysis of acromegaly studies. Journal of Clinical Endocrinology and Metabolism 2009 94 1500-1508.
27. Maison P, Tropeano A-I, Macquin-Mavier I, Giustina A & Chanson P. Impact of somatostatin analogues on the heart in acromegaly: a meta-analysis. Journal of Clinical Endocrinology and Metabolism 2007 92 1743-1747. (Pubitemid 46997181)
28. Cozzi R, Montini M, Attanasio R, Albuizzi M, Lasio G, Lodrini S, Doneda P, Cortesi L & Pagani G. Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumour shrinkage. Journal of Clinical Endocrinology and Metabolism 2006 91 1397-1403.